ClinicalTrials.gg
RecruitingNCT07636928Updated Jul 2, 2026

Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184

A Phase 1 interventional study of VH4524184 and [14C]VH4524184 microdose in HIV Infections, sponsored by ViiV Healthcare. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Planned enrollment
202nd of 210
9 · median 82
Started
2026
with 9 others
Phase 1
83 of 266
9 open now
Primary completion
2026-08
later than 9 of 26 live
Registered
261st of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 202nd largest by planned enrollment of the 210 interventional ones that give a count, is one of 10 that started in 2026, is one of 83 in phase 1, reaches primary completion later than 9 of the 26 other live ones, and was the 261st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of the study is to assess the bioavailability, mass balance, pharmacokinetics, metabolism and excretion of radiolabeled (14C) VH4524184.

03

Conditions studied

  • HIV Infections

Keywords

  • VH4524184
  • Human immunodeficiency virus (HIV)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to sign the Form (ICF).
  2. Sex at birth: male or female; female participants must be of non-, or .
  3. Age: 18 to 55 years, inclusive, at screening.
  4. : 18.0 to 32.0 kg/m\^2, inclusive, at screening.
  5. Female participants of non-childbearing potential must have unequivocal documentation that they are not of childbearing potential Postmenopausal female participants must have a serum follicle-stimulating hormone (FSH) concentration >33.4 milli-international units per milliliter (mIU/mL) at screening to confirm menopause.
  6. Male participants, if not surgically sterilized and who have a female partner of childbearing potential, must agree to use a condom during any sexual intercourse until the completion of the follow-up visit.
  7. Male participants must agree not to donate sperm from admission on Day -1 until the completion of the follow-up visit.
  8. All prescribed medication must have been stopped at least 30 days and >5 half-lives prior to admission to the clinical site on Day -1.
  9. All over-the-counter medication, vitamin preparations and other food supplements, or herbal medications must have been stopped at least 14 days prior to admission to the clinical site on Day -1. An exception is made for paracetamol that is allowed up to admission to the clinical site on Day -1.
  10. Ability and willingness to abstain from alcohol from 48 hours prior to screening and admission to the clinical site on Day -1 until the last PK sample.
  11. Ability and willingness to abstain from methylxanthine-containing beverages or food (coffee, black tea, green tea, white tea, cola, chocolate, energy drinks), and grapefruit (juice) from 48 hours prior to admission to the clinical site.
  12. Good physical and mental health based on medical history, physical examination, clinical laboratory, (ECG), and vital signs, as judged by the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Employee of ICON, the Sponsor, GSK or associated vendors.
  2. History of relevant drug and/or food allergies.
  3. History of drug , delayed-type hypersensitivity, or severe hypersensitivity reactions, as well as history of sensitivity to the study drug.
  4. Using tobacco/nicotine products within 60 days prior to the first study drug administration.
  5. History of alcohol abuse or drug addiction within 5 years prior to screening.
  6. Positive drug and/or alcohol screen at screening or admission to the clinical site.
  7. Average intake of more than 24 units of alcohol per week.
  8. Positive screen for surface antigen (HBsAg), virus (HCV) antibodies, or (HIV) 1 and 2 antibodies at screening.
  9. Participation in a drug study with a small molecule drug within 30 days or 5 half-lives if known (whichever is longer) prior to the first study drug administration in the current study. Participation in a clinical study with a biological within 90 days or 5 half-lives if known (whichever is longer) prior to the first study drug administration in the current study. Participation in 4 or more other drug studies in the 12 months prior to the first study drug administration in the current study.
  10. Donation or loss of more than 450 mL of blood within 60 days prior to the first study drug administration. Donation or loss of more than 1.5 L of blood (for male participants)/more than 1.0 L of blood (for female participants) in the 10 months prior to the first study drug administration in the current study.
  11. Significant and/or acute illness within 14 days prior to the first study drug administration that may impact safety assessments, in the opinion of the Investigator.
  12. Any significant current/ongoing known or suspected pre-existing psychiatric condition, including depression, anxiety, and/or insomnia/sleep disturbances and/or suicidal ideation, in the opinion of the Investigator.
  13. Unsuitable veins for infusion or blood sampling.
  14. Participation in a study with a 14C dose of ≥0.1 megabecquerel (MBq) in the period of 1 year prior to screening.
  15. Irregular defecation pattern.
  16. Pre-existing , in the opinion of the Investigator in discussion with the Sponsor medical monitor, gastro-intestinal pathology or diagnosis, eg, irritable bowel syndrome, inflammatory bowel disease, and/or significant baseline signs and symptoms.
  17. History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drugs, interfering with the interpretation of data or would make the participant unsuitable for the study; unable to comply with dosing requirements; or unable to comply with study visits, in the opinion of the Investigator. The Investigator may contact the Sponsor medical monitor to discuss the inclusion of participants who have a history of specific conditions that are not expected to interfere with their participation in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    VH4524184 Group

    Participants will receive a dose of VH4524184 under fasting conditions, followed by a microdose of radiolabelled \[14C\]VH4524184 administered 2.5 hours after first dose administration at time zero on Day 1 (Period1). After a 14 days wash-out period participants will receive a radiolabelled dose of \[14C\]VH4524184 on Day 15 under fasting conditions.

    Drug: VH4524184 · Drug: [14C]VH4524184 microdose · Drug: [14C]VH4524184

Interventions

  • One dose of VH4524184 is administered to participants at time zero on Day 1 (Period 1).

  • A radiolabelled microdose of \[14C\]VH4524184 is administered 2.5 hours after VH4524184 dose administration on Day 1 (Period1).

  • One dose of radiolabelled \[14C\]VH4524184 is administered to participants at Day 15 (Period 2).

06

What researchers measure

Primary outcomes

  1. Absolute bioavailability (F oral) of VH4524184 (Period 1)

    Time frame: Day 1 up to Day 14

  2. Amount of total radioactivity (TRA) excreted in urine (Ae urine) (Period 1)

    Urine is collected until amount of radioactivity recovered in excreta (urine and feces) is at least 90% of administered radioactivity and \<1% has been recovered from excreta from 2 consecutive days (ie, the total for urine and feces is \<1% on 2 consecutive days).

    Time frame: Day 1 up to Day 14

  3. Amount of TRA excreted in urine (Ae urine) (Period 2)

    Urine is collected until amount of radioactivity recovered in excreta (urine and feces) is at least 90% of administered radioactivity and \<1% has been recovered from excreta from 2 consecutive days (ie, the total for urine and feces is \<1% on 2 consecutive days).

    Time frame: Day 15 up to Day 43

  4. Amount of TRA excreted in feces (Ae feces) (Period 1)

    Feces are collected until amount of radioactivity recovered in excreta (urine and feces) is at least 90% of administered radioactivity and \<1% has been recovered from excreta from 2 consecutive days (ie, the total for urine and feces is \<1% on 2 consecutive days).

    Time frame: Day 1 up to Day 14

  5. Amount of TRA excreted in feces (Ae feces) (Period 2)

    Feces are collected until amount of radioactivity recovered in excreta (urine and feces) is at least 90% of administered radioactivity and \<1% has been recovered from excreta from 2 consecutive days (ie, the total for urine and feces is \<1% on 2 consecutive days).

    Time frame: Day 15 up to Day 43

  6. Amount of TRA excreted in vomitus (Ae vomit) (Period 1)

    Time frame: At Day 1

  7. Amount of TRA excreted in vomitus (Ae vomit) (Period 2)

    Time frame: At Day 15

  8. Total amount of TRA excreted (Ae total) (Period 1)

    The Ae of TRA measured in urine, feces and vomitus (if applicable on Day 1 only). Urine and feces are collected until amount of radioactivity recovered in excreta (urine and feces) is at least 90% of administered radioactivity and \<1% has been recovered from excreta from 2 consecutive days (ie, the total for urine and feces is \<1% on 2 consecutive days).

    Time frame: From Day 1 up to Day 14

  9. Total amount of TRA excreted (Ae total) (Period 2)

    The Ae of TRA measured in urine, feces and vomitus (if applicable on Day 15 only). Urine and feces are collected until amount of radioactivity recovered in excreta (urine and feces) is at least 90% of administered radioactivity and \<1% has been recovered from excreta from 2 consecutive days (ie, the total for urine and feces is \<1% on 2 consecutive days).

    Time frame: Day 15 up to Day 43

  10. Fraction of TRA excreted in urine (fe urine) (Period 1)

    Urine is collected until the amount of radioactivity recovered in excreta (urine and feces) is at least 90% of administered radioactivity and \<1% has been recovered from excreta from 2 consecutive days (ie, the total for urine and feces is \<1% on 2 consecutive days).

    Time frame: Day 1 up to Day 14

  11. Fraction of TRA excreted in urine (fe urine) (Period 2)

    Urine is collected until amount of radioactivity recovered in excreta (urine and feces) is at least 90% of administered radioactivity and \<1% has been recovered from excreta from 2 consecutive days (ie, the total for urine and feces is \<1% on 2 consecutive days).

    Time frame: Day 15 up to Day 43

  12. Fraction of TRA excreted in feces (fe feces) (Period 1)

    Feces is collected until amount of radioactivity recovered in excreta (urine and feces) is at least 90% of administered radioactivity and \<1% has been recovered from excreta from 2 consecutive days (ie, the total for urine and feces is \<1% on 2 consecutive days).

    Time frame: Day 1 up to Day 14

  13. Fraction of TRA excreted in feces (fe feces) (Period 2)

    Feces is collected until amount of radioactivity recovered in excreta (urine and feces) is at least 90% of administered radioactivity and \<1% has been recovered from excreta from 2 consecutive days (ie, the total for urine and feces is \<1% on 2 consecutive days).

    Time frame: Day 15 up to Day 43

  14. Fraction of TRA excreted in vomitus (fe vomit) (Period 1)

    Time frame: At Day 1

  15. Fraction of TRA excreted in vomitus (fe vomit) (Period 2)

    Time frame: At Day 15

  16. Total fraction of TRA excreted (fe total) (Period 1)

    The fe of TRA measured in urine, feces and vomitus (if applicable on Day 1 only). Urine and feces are collected until amount of radioactivity recovered in excreta (urine and feces) is at least 90% of administered radioactivity and \<1% has been recovered from excreta from 2 consecutive days (ie, the total for urine and feces is \<1% on 2 consecutive days).

    Time frame: Day 1 up to Day 14

  17. Total fraction of TRA excreted (fe total) (Period 2)

    The fe of TRA measured in urine, feces and vomitus (if applicable on Day 15 only). Urine and feces are collected until amount of radioactivity recovered in excreta (urine and feces) is at least 90% of administered radioactivity and \<1% has been recovered from excreta from 2 consecutive days (ie, the total for urine and feces is \<1% on 2 consecutive days).

    Time frame: Day 15 up to Day 43

  18. Maximum concentration (Cmax) of VH4524184 in plasma (Period 1)

    Time frame: Day 1 to Day 14

  19. Maximum concentration (Cmax) of VH4524184 in plasma (Period 2)

    Time frame: Day 15 to Day 43

  20. Maximum concentration (Cmax) of [14C]VH4524184 in plasma (Period 1)

    Time frame: Day 1 to Day 14

  21. Maximum concentration (Cmax) of TRA in plasma (Period 1)

    Time frame: Day 1 to Day 14

  22. Maximum concentration (Cmax) of TRA in plasma (Period 2)

    Time frame: Day 15 to Day 43

  23. Cmax of TRA in whole blood (Period 1)

    Time frame: Day 1 to Day 14

  24. Cmax of TRA in whole blood (Period 2)

    Time frame: Day 15 to Day 43

  25. Time to maximum concentration (tmax) of VH4524184 in plasma (Period 1)

    Time frame: Day 1 to Day 14

  26. Time to maximum concentration (tmax) of VH4524184 in plasma (Period 2)

    Time frame: Day 15 to Day 43

  27. Time to maximum concentration (tmax) of [14C]VH4524184 in plasma (Period 1)

    Time frame: Day 1 to Day 14

  28. Time to maximum concentration (tmax) of TRA in plasma (Period 1)

    Time frame: Day 1 to Day 14

  29. Time to maximum concentration (tmax) of TRA in plasma (Period 2)

    Time frame: Day 15 to Day 43

  30. Time to maximum concentration (tmax) of TRA in whole blood (Period 1)

    Time frame: Day 1 to Day 14

  31. Time to maximum concentration (tmax) of TRA in whole blood (Period 2)

    Time frame: Day 15 to Day 43

  32. Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of VH4524184 in plasma (Period 1)

    Time frame: Day 1 to Day 14

  33. Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of VH4524184 in plasma (Period 2)

    Time frame: Day 15 to Day 43

  34. Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of [14C]VH4524184 in plasma (Period 1)

    Time frame: Day 1 to Day 14

  35. Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of TRA in plasma (Period 1)

    Time frame: Day 1 to Day 14

  36. Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of TRA in plasma (Period 2)

    Time frame: Day 15 to Day 43

  37. Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of TRA in whole blood (Period 1)

    Time frame: Day 1 to Day 14

  38. Area under the concentration-time curve from time zero to the last measured timepoint (AUC 0-t) of TRA in whole blood (Period 2)

    Time frame: Day 15 to Day 43

  39. Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of VH4524184 in plasma (Period 1)

    Time frame: Day 1 to Day 14

  40. Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of VH4524184 in plasma (Period 2)

    Time frame: Day 15 up to Day 43

  41. Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of [14C]VH4524184 in plasma (Period 1)

    Time frame: Day 1 to Day 14

  42. Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of TRA in plasma (Period 1)

    Time frame: Day 1 to Day 14

  43. Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of TRA in plasma (Period 2)

    Time frame: Day 15 to 43

  44. Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of TRA in whole blood (Period 1)

    Time frame: Day 1 to Day 14

  45. Area under the concentration-time curve from time zero to infinity (AUC 0-inf) of TRA in whole blood (Period 2)

    Time frame: Day 15 to Day 43

  46. Amount of VH4524184 excreted in urine (Ae urine) (Period 2)

    Time frame: Day 15 to Day 43

  47. Fraction of VH4524184 excreted in urine (fe urine) (Period 2)

    Time frame: Day 15 to Day 43

  48. Renal clearance of VH4524184 (CL R) (Period 2)

    Time frame: Day 15 to Day 43

Secondary outcomes

  1. Number of participants with adverse events (AE), overall and by severity (Periods 1 and 2)

    Time frame: Day 1 to Day 50

  2. Number of participants who discontinue treatment due to AEs (Periods 1 and 2)

    Time frame: Day 1 to Day 50

  3. Change from baseline for aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, and alkaline phosphatase (Periods 1 and 2)

    Time frame: On Days 2, 14, 16, 28 and 42

  4. Maximum toxicity grade increase from baseline for AST, ALT, total bilirubin, and alkaline phosphatase (Periods 1 and 2)

    Time frame: On Days 2, 14, 16, 28 and 42

  5. Blood to plasma ratio of TRA (Periods 1 and 2)

    Cmax, AUC(0-t) and AUC(0-inf) TRA measured in whole blood compared to Cmax, AUC(0-t) and AUC(0-inf) TRA measured in plasma in Period 1 and Period 2.

    Time frame: Day 1 to Day 14 (Period 1) and Day 15 to Day 28 (Period 2)

07

Study locations

1 of 1 sites recruiting
  • GSK Investigational Site
    Groningen, 9728 NZ, Netherlands
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.viiv-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Aug 2026, 2 months after the start.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's planned 2 months is below that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 9, 2026
StartActual
Jun 4, 2026
Primary completionEst.
Aug 20, 2026
CompletionEst.
Aug 20, 2026
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07636928
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Jun 9, 2026
Start date
Jun 4, 2026
Primary completion
Aug 20, 2026 (estimated)
Completion
Aug 20, 2026 (estimated)
Last update
Jul 2, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VH4524184

Start the discussion